Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Venture capital firm investing in early- and mid-stage healthcare and life sciences companies with product innovations.
Key people at Alafi Capital.
Alafi Capital is a venture capital firm based in San Francisco, California, that specializes in early and mid-stage investments across the healthcare, biotechnology, life sciences, and medical device sectors. The firm generates returns by providing equity funding to product-oriented innovations in the United States and Europe, holding an estimated net worth position of at least $521 million as a major biopharmaceutical shareholder. Alafi Capital has backed multiple life science enterprises, with a historical portfolio that includes established companies such as Amgen, Biogen, Qiagen, and Applied Biosystems. In recent years, the firm has continued its investment strategy by participating as a co-investor in a $24 million Series A and a subsequent $71 million Series B funding round for Resolve BioSciences. Alafi Capital was founded in 1999 by Christopher D. Alafi, succeeding a venture firm established by Moshe Alafi.
Alafi Capital is a private venture capital firm based in California that specializes in early- and mid-stage investments primarily in the healthcare sector across the United States and Europe. Its investment focus includes product-oriented biotechnology, life sciences technologies, imaging, diagnostics, and medical devices. The firm aims to back companies with strong growth potential that are developing innovative healthcare solutions, thereby contributing to advancements in patient outcomes and medical technology. Notable portfolio companies include Bolt Threads, Assurex Health, Kreatech Diagnostics, Natera, and Stereotaxis, reflecting its commitment to fostering innovation in healthcare[1][2][3].
Founded in 1995 in San Francisco, Alafi Capital has over 25 years of experience in healthcare venture investing. The firm was established with a focus on supporting early and mid-stage companies that align with its expertise in healthcare and life sciences. Key partners include Christopher (Chris) Alafi, Managing Partner, and Bill Weiss, Chief Financial Officer. Over time, Alafi Capital has evolved to maintain a strong presence in both the U.S. and European markets, consistently targeting companies that demonstrate potential for significant impact in biotechnology and medical devices[1][2][6].
Alafi Capital rides the ongoing trend of innovation in healthcare technology, particularly in biotechnology and medical devices, sectors that are rapidly evolving due to advances in genomics, diagnostics, and personalized medicine. The timing is favorable given increasing global demand for improved healthcare solutions and the digitization of medical technologies. By investing in early-stage companies, Alafi Capital helps accelerate the development and commercialization of breakthrough healthcare products, influencing the broader ecosystem by enabling startups to scale and bring impactful innovations to market[1][2][3].
Looking ahead, Alafi Capital is poised to continue leveraging its deep sector expertise to identify emerging healthcare technologies with transformative potential. Trends such as precision medicine, AI-driven diagnostics, and novel biotech therapies will likely shape its investment focus. The firm’s influence may grow as it supports companies that address unmet medical needs and improve patient care globally. Its established network and track record position it well to capitalize on evolving healthcare market dynamics and maintain a leadership role in venture investing within this critical sector[1][2][3].
Alafi Capital has 9 tracked investments across 5 companies. The latest tracked deal is $71.0M Series B in Resolve BioSciences in October 2022.
Key people at Alafi Capital.
